Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining ...
TipRanks on MSN
Eli Lilly’s phase 2 study on imlunestrant: A potential game-changer in breast cancer treatment
Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
SHELTON, CT, December 9, 2025 (EZ Newswire) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) today reported that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback